News
Weight-loss jabs will be made available to the poorest who have the highest need, the Government has said in the NHS 10-year ...
Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly and Novo Nordisk are competing for ...
Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...
Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?
Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...
19h
inews.co.uk on MSNWeight loss jabs to be given to 3,000 people in trial to get them back into workWeight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper ...
Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...
A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...
For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...
For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...
Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results